Aptevo Therapeutics Inc. (APVO)

NASDAQ: APVO · Real-Time Price · USD
3.250
-0.920 (-22.06%)
At close: Jun 23, 2025, 4:00 PM
3.230
-0.020 (-0.62%)
After-hours: Jun 23, 2025, 7:59 PM EDT
-22.06%
Market Cap 12.04M
Revenue (ttm) n/a
Net Income (ttm) -23.70M
Shares Out 3.71M
EPS (ttm) -745.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,286,818
Open 3.880
Previous Close 4.170
Day's Range 3.190 - 3.925
52-Week Range 2.810 - 485.366
Beta 5.73
Analysts Strong Buy
Price Target 5,920.00 (+182,053.85%)
Earnings Date Aug 7, 2025

About APVO

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute mye... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 37
Stock Exchange NASDAQ
Ticker Symbol APVO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for APVO stock is "Strong Buy" and the 12-month stock price forecast is $5,920.0.

Price Target
$5,920.0
(182,053.85% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on...

3 days ago - Accesswire

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipl...

3 days ago - Accesswire

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.

Other symbols: SWBI
3 days ago - Benzinga

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia s...

5 days ago - Market Watch

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Aptevo Therapeutics Inc APVO stock is surging on Wednesday.

5 days ago - Benzinga

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its pro...

5 days ago - Accesswire

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed ...

5 days ago - Accesswire

Aptevo Participating in the BIO International Convention

SEATTLE, WA / ACCESS Newswire / June 13, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its pro...

10 days ago - Accesswire

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

SEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares ...

4 weeks ago - Accesswire

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine rele...

5 weeks ago - Accesswire

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical st...

6 weeks ago - Accesswire

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...

2 months ago - Accesswire

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...

2 months ago - Accesswire

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

SEATTLE, WASHINGTON / ACCESS Newswire / April 4, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-on...

2 months ago - Accesswire

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

SEATTLE, WA / ACCESS Newswire / April 3, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology t...

2 months ago - Accesswire

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform d...

3 months ago - Accesswire

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a l...

3 months ago - Accesswire

Aptevo to Participate in March Conferences

SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its pro...

3 months ago - Accesswire

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth ORLANDO, FL / ACCESS Newswire / February 15, 2025 / RedChip Companies announced today that an interview with A...

4 months ago - Accesswire

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% ...

4 months ago - Accesswire

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a ...

5 months ago - Accesswire

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology th...

6 months ago - Accesswire

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing SEATT...

6 months ago - Accesswire

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a ...

7 months ago - Accesswire

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

SEATTLE, WA / ACCESSWIRE / November 29, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares ...

7 months ago - Accesswire